Benefits of Conventional Chemotherapy in Progressive Disease Patients with Tyrosine-Kinase Inhibitors: A Case Report

Background. Mutation of the epidermal growth factor receptor (EGFR) in non-small cell lung carcinoma is a favorable predictive for targeted EGFR tyrosine kinase inhibitor (TKI) therapy, but patients with EGFR-mutated cancer who are given EGFR-TKI will experience disease progression after average 10 to 14 months on average. This study aims describe case progressive adenocarcinoma and its chemotherapy treatment.
 Case presentation: A 54 years old woman came stage IV left (exon 21 mutation) had received TKI 17 progressed, so treatment was shifted systemic chemotherapy. Based these diagnostic results, patient diagnosed T3N1M1c (pleura, contralateral nodule, ribs, suprarenal) Stage IVb PS ECOG 0. The then treated conventional doublet-platinum-based Carboplatin-Paclitaxel combination.
 Conclusion: Systemic doublet-platinum an option cannot obtain tissue histopathological examination at rebiopsy or do not have access advanced molecular biology (e.g., T790M) follow-up therapy (third-generation TKI, osimertinib).